



Universiteit
Leiden
The Netherlands

Lymphoproliferative Disease in the Rectum 4 Years After Local Mesenchymal Stromal Cell Therapy for Refractory Perianal Crohn's Fistulas: A Case Report

Barnhoorn, M.C.; Halteren, A.G.S. van; Pel, M. van; Molendijk, I.; Struijk, A.C.; Jansen, P.M.; ... ; Meulen-de Jong, A.E. van der

Citation

Barnhoorn, M. C., Halteren, A. G. S. van, Pel, M. van, Molendijk, I., Struijk, A. C., Jansen, P. M., ... Meulen-de Jong, A. E. van der. (2019). Lymphoproliferative Disease in the Rectum 4 Years After Local Mesenchymal Stromal Cell Therapy for Refractory Perianal Crohn's Fistulas: A Case Report. *Journal Of Crohn's And Colitis*, 13(6), 807-811. doi:10.1093/ecco-jcc/jjy220

Version: Not Applicable (or Unknown)

License: [Leiden University Non-exclusive license](#)

Downloaded from: <https://hdl.handle.net/1887/119969>

Note: To cite this publication please use the final published version (if applicable).



Short Report

Lymphoproliferative Disease in the Rectum 4 Years After Local Mesenchymal Stromal Cell Therapy for Refractory Perianal Crohn's Fistulas: A Case Report

Marieke C. Barnhoorn^a, Astrid G.S. van Halteren^b, Melissa van Pel^c,
Ilse Molendijk^a, Ada C. Struijk^d, Patty M. Jansen^e,
Hein W. Verspaget^a, Gerard Dijkstra^f, Liesbeth E.M. Oosten^c,
Andrea E. van der Meulen – de Jong^a

^aDepartment of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands
^bWillem-Alexander Children's Hospital, Immunology Laboratory, Leiden University Medical Center, Leiden, The Netherlands
^cDepartment of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands
^dDepartment of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands
^eDepartment of Pathology, Leiden University Medical Center, Leiden, The Netherlands
^fDepartment of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Corresponding author: Andrea E. van der Meulen – de Jong, Leiden University Medical Center, Department of Gastroenterology and Hepatology, PO box 9600, C4-P, 2300 RC Leiden, The Netherlands. Tel: +31-71-526-2915; Fax: +31715248115; Email: a.e.meulen@lumc.nl

Abstract

Mesenchymal stromal cell [MSC] therapy is a new treatment for perianal fistulas in Crohn's disease. Although MSC therapy shows a favourable safety profile, long-term safety data are limited. We detected an Epstein Barr virus [EBV]-associated B cell lymphoproliferative lesion in the rectum of a patient 4 years after local administration of MSCs for his perianal fistulas. To investigate whether MSC therapy contributed to the development of this lymphoproliferative disease, we analyzed the possibility of EBV transfer via the MSC product and the persistence of MSCs in the lymphoproliferative lesion using short tandem repeat analysis.

Key Words: perianal fistulas; Crohn's disease; mesenchymal stromal cells; lymphoproliferative disease.

1. Introduction

In 2014, we conducted a dose-finding placebo-controlled clinical trial in which allogeneic bone marrow-derived mesenchymal stromal cells [MSCs] were administered locally to Crohn's disease [CD] patients with refractory perianal fistulas.¹ Fistula healing at week 6 was observed in 80% of the patients treated with 30×10^6 MSCs, compared with 17% in the placebo group. Four years later, we invited 20 study patients for long-term follow-up and performed

endoscopy of the rectum and pelvic MRI. Here, we report a case of lymphoproliferative disease [LPD] in the rectum detected 4 years after MSC therapy for perianal fistulizing CD.

2. Case report

One of the patients treated with a local injection of 30×10^6 MSCs was a 45-year-old man. In 2008, he was diagnosed with CD of the




Figure 1. LPD in the rectum of patient previously treated with local MSC therapy. [A] Ulcer in the rectum with a raised edge next to the scar of the old fistula opening after biopsy. [B] Routine immunohistochemistry performed on biopsy from the lesion using the classical markers PAX5, CD20, CD30, CD15, and CD45. *In situ* hybridisation [dark staining] for Epstein-Barr encoding region [EBER] to detect EBV in the lesion. [C] MRI-scan of the abdomen within the coronal plane para-aortal multiple lymphoproliferative processes around the a. mesenterica inferior and in the axial plane multiple lymphoproliferative processes surrounding the a. and v. iliaca interna.

colon, predominantly left-sided. In 2012, he developed a trans-sphincteric fistula with one internal and two external openings. He

was treated with prednisone [2008], azathioprine [2008–2012], adalimumab [2011–2012], and methotrexate [2012–2017]. Since

MSC therapy in 2014, his fistula was closed. In 2016, he started with vedolizumab, which he has continued since, because of a luminal exacerbation. Surveillance endoscopy in the summer of 2017 revealed no abnormalities and normal pathology of biopsies.

At the long-term follow-up visit, 4 years after MSC therapy, the patient reported no complaints and had a normal faecal calprotectin of 46 µg/g. The scheduled MRI at this visit showed fibrosis of the distal part of the fistula tract. The cranial part of the fistula was no longer visible. During scheduled proctoscopy, an ulcer next to the scar of the old fistula opening was seen with a raised edge. The diameter was ~10 mm [Figure 1A]. Biopsies were obtained and histology revealed the presence of an Epstein-Barr virus [EBV]-associated B cell LPD [Figure 1B]. The lesion contained a combination of small lymphocytes and blastoid cells, positive for EBV-encoded RNA and expressing PAX-5, CD20, CD15, and to a lesser extent CD30 [Figure 1B]. Laboratory tests showed a low level of EBV virus-specific DNA in his serum. Of note, our patient was IgG EBV-positive, but IgM EBV-negative at the time of MSC therapy in 2014. A subsequent CT scan of the abdomen and thorax showed the presence of extensive lymphadenopathy [Figure 1C]. The patient was diagnosed with Lugano Stage IV EBV-associated B cell LPD and was treated successfully with chemotherapy.

Retrospective analysis of the biopsies of the rectum taken in 2014 excluded the presence of LPD prior to MSC administration, because no rectum localization of EBV could be detected using EBV-encoded RNA *in situ* hybridization. Next, we investigated a potential role for MSC therapy in the development of this LPD, considering the following options: 1. Transfer of LPD via the MSC Drug Product; 2. Transfer of EBV via the MSC Drug Product; 3. Tumorigenicity due to persisting local allogeneic MSCs. Regarding the first option, theoretically, an LPD present in the MSC Drug Product could be transferred to the patient. However, no CD45+ cells, and thereby B cells, were detected in the MSC Drug Product [10 000 cells screened]. This was in accordance with the release criteria for MSC Drug Products generated for this study [≤1% CD45+ cells]. Additionally, all treating physicians of all other patients who received an MSC Drug Product obtained from the same donor [*n* = 9, Table 1] were contacted about the potential presence of LPDs in their patients. No LPDs were reported in the other patients treated with MSCs obtained from this donor bone marrow. Furthermore, at the time of bone marrow donation, the MSC donor was in good health, without any signs of LPD.

The MSC-donor was positive for IgG EBV at the time of bone marrow donation. To investigate a potential transfer of EBV-virus to the recipient using MSCs as a vehicle, the MSCs that were infused in the patient and two other MSC Drug Products obtained from donors positive for IgG EBV at the time of bone marrow donation were tested for the presence of EBV-specific DNA using PCR. No

EBV-DNA was detected in the MSCs infused in this patient; nor was there any in the other Drug Products that were tested.

To investigate whether the injected MSCs were still present in the lesion in the rectum, flow cytometry sorting was used to separate cells in rectum biopsies into CD45+CD19^{dim/+} and CD45-CD15^{dim/+} cells [Figure 2A, panel A: representing healthy and malignant B-cells], and a CD45-CD15- fraction [Figure 2A, panel B: representing the stromal-epithelial population, which would include the allogeneic MSCs, if still present]. Standard short tandem repeat [STR] analysis was used to examine the presence of genomic material of the MSC donor in both sorted cell fractions, as well as in 20 000 unfractionated cells obtained from the same biopsy. Although cell counts and DNA recovery was low, some STR regions on nuclear DNA could be evaluated successfully. All fractions exclusively showed the STR profile of the patient. Together, these data indicated that no allogeneic MSCs were present in the biopsied rectal lymphoma [Figure 2B].

3. Discussion


In this report we present a patient diagnosed with LPD in the rectum 4 years after local MSC therapy for perianal fistulizing CD. We hypothesized that the occurrence of LPD in this patient could be explained by his underlying IBD, prolonged use of immunosuppressive medication, including methotrexate, vedolizumab, anti-tumor necrosis factor [TNF]-therapy, and azathioprine, or local MSC infusion.

Studies on the risk of LPD in patients with IBD generated conflicting results. In contrast to rheumatoid arthritis, IBD itself does not seem to cause a statistically significant increased risk of LPD.²⁻⁶ However, IBD patients using immunosuppressive medication have an increased risk of LPD.² These LPDs are often extranodal and are the result of EBV-driven processes, although other infectious agents could also be involved.^{2,7} Our patient used several immunosuppressive therapies in the last 10 years, and each of these treatments is associated with an increased risk of developing LPD. Until 5 months before LPD diagnosis, the patient was using methotrexate as an immunosuppressive therapy. Methotrexate-associated LPD is recognized as an independent entity and is characterized by the presence of EBV virus in the lymphoma tissue. In most patients, a regression of the LPD is seen after discontinuation of methotrexate.⁸ At the time of LPD diagnosis, the patient was treated with vedolizumab. As vedolizumab has only been available for a few years, extensive data on the long-term safety profile are not available yet.⁹ Furthermore, our patient had used azathioprine for 4 years and anti-TNF therapy in the past. Although, current use of thiopurines in IBD is associated with an increased risk of LPD, conflicting data are available about the risk of LPD after withdrawing thiopurines and anti-TNF

Table 1. Overview of other patients treated with MSCs from the same donor as our patient.

	Age at time of treatment (years)	Gender	Indication for MSC therapy	Time of follow-up [months]	LPD reported
1	33	V	CD fistula, MSC-F trial	48	No
2	30	V	CD fistula, MSC-F trial	48	No
3	22	M	CD fistula, MSC-F trial	48	No
4	9	M	GvHD, Study P05.089	5.5	No
5	10	V	GvHD, Study P05.089	<1	No
6	15	V	GvHD, Study P05.089	10	No
7	42	M	GvHD, hospital exemption	50	No
8	39	V	GvHD, hospital exemption	3.5	No

CD, Crohn's disease; GvHD, steroid refractory graft-versus-host disease; LPD, lymphoproliferative disease; MSC-F trial,¹ Study P05.089 [LUMC].¹⁹



treatment.^{2,10–13} Therefore, we cannot exclude the possibility that the patient developed LPD as a result of immunosuppressive therapy other than a single MSC gift in 2014.

As MSCs have immunomodulatory properties and may have served as a vehicle for EBV-transfer, we investigated the potential role of MSC therapy in this LPD. We excluded the possibility that the EBV virus was transferred via the infused MSC or by contaminating EBV-positive B cells present in the MSC Drug Product. Furthermore, we did not detect any allogeneic MSCs or DNA specific for the MSC donor in the lesion in the rectum. No data are available on the risk of LPD in patients who have received MSC therapy. Overall, intravenous MSC therapy does not seem to be associated with significant immunosuppression in immunocompetent individuals.¹⁴ However, an additional immunosuppressive effect in patients already on immunosuppressive medication cannot be excluded. In 52 renal transplant patients treated in our centre with intravenous MSCs, no LPD was reported [follow up 6 months–4 years]. However, in the literature, two cases of EBV-associated LPD after systemic MSC treatment are described in patients with Graft-versus-Host Disease,^{15,16} a severely immunocompromised patient population. No data are available on LPD following the local injection of MSCs.

Taken together, it is highly unlikely that this EBV-associated LPD was directly related to MSC therapy, but rather it is likely to have been the result of prolonged immunosuppressive therapy. However, we cannot exclude the possibility of additional local immunosuppression by MSC therapy, which subsequently may drive proliferation of tissue-resident EBV-infected cells. Darvadstrocel,¹⁷ a product containing MSCs isolated from adipose tissue, is now approved in Europe as a treatment for complex perianal fistulas in patients with Crohn's disease. One year follow-up data showed a favorable safety profile of this product.¹⁸ This case report shows that more long-term reports on MSC therapy in perianal fistulas from clinical trials and daily practice are needed to evaluate the complete safety profile of topical MSC therapy.

Author Contributions

MCB: study design, acquisition of data, data analysis, and writing up first draft of the paper; AGSH: study design, acquisition of data, data analysis, and revising the article; MP: study design, acquisition of data, and revising the article; IM: inclusion of patients, and revising the article; ACS: acquisition of data, and data analysis; PMJ: acquisition of data, and data analysis; HWV: study design, and revising the article; GD: acquisition of data, revising the article; LEMO: study design, acquisition of data, revising the article; AEMJ: study design, revising the article.

Funding

There has been no specific funding for this work.

Conflict of interest

The authors declare that they have no conflicts to declare.

Acknowledgments

Written informed consent prior to submission was obtained from the patient.

Supplementary Data

Supplementary data are available at ECCO-JCC online.

References

1. Molendijk I, Bonsing BA, Roelofs H, *et al*. Allogeneic bone marrow-derived mesenchymal stromal cells promote healing of refractory perianal fistulas in patients with Crohn's disease. *Gastroenterology* 2015;149:918–27.e6.
2. Magro F, Peyrin-Biroulet L, Sokol H, *et al*. Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop [III]. *J Crohns Colitis* 2014;8:31–44.
3. Biancone L, Zuzzi S, Ranieri M, *et al*. Fistulizing pattern in Crohn's disease and pancolitis in ulcerative colitis are independent risk factors for cancer: a single-center cohort study. *J Crohns Colitis* 2012;6:578–87.
4. Fallah M, Liu X, Ji J, Försti A, Sundquist K, Hemminki K. Autoimmune diseases associated with non-Hodgkin lymphoma: a nationwide cohort study. *Ann Oncol* 2014;25:2025–30.
5. Jung YS, Han M, Park S, Kim WH, Cheon JH. Cancer risk in the early stages of inflammatory bowel disease in Korean patients: a nationwide population-based study. *J Crohns Colitis* 2017;11:954–62.
6. Lewis JD, Bilker WB, Brensinger C, Deren JJ, Vaughn DJ, Strom BL. Inflammatory bowel disease is not associated with an increased risk of lymphoma. *Gastroenterology* 2001;121:1080–7.
7. Tran H, Nourse J, Hall S, Green M, Griffiths L, Gandhi MK. Immunodeficiency-associated lymphomas. *Blood Rev* 2008;22:261–81.
8. Rizzi R, Curci P, Delia M, *et al*. Spontaneous remission of "methotrexate-associated lymphoproliferative disorders" after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature. *Med Oncol* 2009;26:1–9.
9. Argollo M, Fiorino G, Peyrin-Biroulet L, Danese S. Vedolizumab for the treatment of Crohn's disease. *Expert Rev Clin Immunol* 2018;14:179–89.
10. Herrinton LJ, Liu L, Weng X, Lewis JD, Hutfless S, Allison JE. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. *Am J Gastroenterol* 2011;106:2146–53.
11. Mariette X, Matucci-Cerinic M, Pavelka K, *et al*. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. *Ann Rheum Dis* 2011;70:1895–904.
12. Yang C, Huang J, Huang X, *et al*. Risk of lymphoma in patients with inflammatory bowel disease treated with anti-tumor necrosis factor alpha agents: a systematic review and meta-analysis. *J Crohns Colitis* 2018, published online May 12 DOI: 10.1093/ecco-jcc/jjy065
13. Beaugerie L, Brousse N, Bouvier AM, *et al*; CESAME Study Group. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. *Lancet* 2009;374:1617–25.
14. Lalu MM, McIntyre L, Pugliese C, *et al*; Canadian Critical Care Trials Group. Safety of cell therapy with mesenchymal stromal cells [SafeCell]: a systematic review and meta-analysis of clinical trials. *Plos One* 2012;7:e47559.
15. Zhao K, Lou R, Huang F, *et al*. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant* 2015;21:97–104.
16. Ringdén O, Uzunel M, Rasmussen I, *et al*. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. *Transplantation* 2006;81:1390–7.
17. Panés J, García-Olmo D, Van Assche G, *et al*; ADMIRE CD Study Group Collaborators. Expanded allogeneic adipose-derived mesenchymal stem cells [Cx601] for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. *Lancet* 2016;388:1281–90.
18. Panés J, García-Olmo D, Van Assche G, *et al*; ADMIRE CD Study Group Collaborators. Long-term efficacy and safety of stem cell therapy [Cx601] for complex perianal fistulas in patients with Crohn's disease. *Gastroenterology* 2018;154:1334–1342.e4.
19. Ball LM, Bernardo ME, Roelofs H, *et al*. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III–IV acute graft-versus-host disease. *Br J Haematol* 2013;163:501–9.